Skip to main content
Erschienen in: Supportive Care in Cancer 7/2005

01.07.2005 | Short Communication

Treating sialorrhea with transdermal scopolamine. Exploiting a side effect to treat an uncommon symptom in cancer patients

verfasst von: Davide Tassinari, Barbara Poggi, Manuela Fantini, Emiliano Tamburini, Sergio Sartori

Erschienen in: Supportive Care in Cancer | Ausgabe 7/2005

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Sialorrhea is a distressing symptom accompanying oral cancer and many heterogeneous cancer-related conditions (chemotherapy-induced nausea, bowel subocclusion, pharmacologic side effects), but its incidence is low in cancer patients. Conversely, it is frequent in patients with neurological damage, and some therapeutic options have been attempted such as botulinum toxins, anticholinergic agents, and surgical procedures.

Case report

We report the case of an 80-year-old woman with peritoneal carcinomatosis and bowel subocclusion, suffering from distressing nausea and sialorrhea that rapidly improved using transdermal scopolamine. No relevant side effects occurred during the treatment, and the reduction of the abnormal salivation allowed the recovery of oral feeding.

Conclusions

Anticholinergic drugs are classified as secondary options in the treatment of sialorrhea of patients with Parkinson’s disease or cerebral palsy, owing to the relevant side effects occurring during prolonged treatments. However, they could be useful in cancer patients with bowel subocclusion, as the reduction of gastrointestinal secretions and intestinal motility (frequent side effects of anticholinergic drugs) could be effective in controlling nausea, vomiting, and abdominal pain. Moreover, the transdermal or sublingual route of administration can be of some interest, avoiding other more invasive parenteral approaches.
Literatur
1.
Zurück zum Zitat Bachrach SJ, Walter RS, Trzcinski K (1998) Use of glycopyrrolate and other anticholinergic medications for sialorrhea in children with cerebral palsy. Clin Pediatr (Phila) 37(8):485–490 Bachrach SJ, Walter RS, Trzcinski K (1998) Use of glycopyrrolate and other anticholinergic medications for sialorrhea in children with cerebral palsy. Clin Pediatr (Phila) 37(8):485–490
2.
Zurück zum Zitat Bennett M, Lucas V, Brennan M et al (2002) Using anti-muscarinic drugs in the management of death rattle: evidence-based guidelines for palliative care. Palliat Med 16(5):369–374CrossRefPubMed Bennett M, Lucas V, Brennan M et al (2002) Using anti-muscarinic drugs in the management of death rattle: evidence-based guidelines for palliative care. Palliat Med 16(5):369–374CrossRefPubMed
3.
Zurück zum Zitat De Conno F, Sbanotto A, Ripamonti C, Ventafridda V (2004) Mouth care. In: Doyle D, Hanks G, Cherny N, Calman K (eds) Oxford textbook of palliative medicine, 3rd edn. Oxford University Press, New York, pp 673–687 De Conno F, Sbanotto A, Ripamonti C, Ventafridda V (2004) Mouth care. In: Doyle D, Hanks G, Cherny N, Calman K (eds) Oxford textbook of palliative medicine, 3rd edn. Oxford University Press, New York, pp 673–687
4.
Zurück zum Zitat Friedman A, Potulska A (2001) Botulinum toxin for treatment of parkinsonian sialorrhea. Neurol Neurochir Pol 35(Suppl 3):23–27 Friedman A, Potulska A (2001) Botulinum toxin for treatment of parkinsonian sialorrhea. Neurol Neurochir Pol 35(Suppl 3):23–27
5.
Zurück zum Zitat Hockstein NG, Samadi DS, Gendron K, Handler SD (2004) Sialorrhea: a management challenge. Am Fam Phys 69(11):2628–2634 Hockstein NG, Samadi DS, Gendron K, Handler SD (2004) Sialorrhea: a management challenge. Am Fam Phys 69(11):2628–2634
6.
Zurück zum Zitat Hyson HC, Johnson AM, Jog MS (2002) Sublingual atropine for sialorrhea secondary to parkinsonism: a pilot study. Mov Disord 17(6):1318–1320CrossRefPubMed Hyson HC, Johnson AM, Jog MS (2002) Sublingual atropine for sialorrhea secondary to parkinsonism: a pilot study. Mov Disord 17(6):1318–1320CrossRefPubMed
7.
Zurück zum Zitat Mercadante S, Ripamonti C, Casuccio A, Zecca E, Groff L (2000) Comparison of octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant inoperable bowel obstruction. Support Care Cancer 8(3):188–191CrossRefPubMed Mercadante S, Ripamonti C, Casuccio A, Zecca E, Groff L (2000) Comparison of octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant inoperable bowel obstruction. Support Care Cancer 8(3):188–191CrossRefPubMed
8.
Zurück zum Zitat Ondo WG, Hunter C, Moore W (2004) A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson’s disease. Neurology 62(1):37–40PubMed Ondo WG, Hunter C, Moore W (2004) A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson’s disease. Neurology 62(1):37–40PubMed
9.
Zurück zum Zitat Potter J, Hami F, Bryan T, Quigley C (2003) Symptoms in 400 patients referred to palliative care services: prevalence and patterns. Palliat Med 17(4):310–314CrossRefPubMed Potter J, Hami F, Bryan T, Quigley C (2003) Symptoms in 400 patients referred to palliative care services: prevalence and patterns. Palliat Med 17(4):310–314CrossRefPubMed
10.
Zurück zum Zitat Ripamonti C, Mercadante S, Groff L et al (2000) Role of octreotide, scopolamine butylbromide and hydration in symptom control of patients with inoperable bowel obstruction and nasogastric tubes: a prospective randomized trial. J Pain Symptom Manage 19(1):23–34CrossRefPubMed Ripamonti C, Mercadante S, Groff L et al (2000) Role of octreotide, scopolamine butylbromide and hydration in symptom control of patients with inoperable bowel obstruction and nasogastric tubes: a prospective randomized trial. J Pain Symptom Manage 19(1):23–34CrossRefPubMed
11.
Zurück zum Zitat Ripamonti C, Twycross R, Baines M et al (2001) Clinical practice recommendations for the management of bowel obstruction in patients with end-stage cancer. Support Care Cancer 9:223–233CrossRefPubMed Ripamonti C, Twycross R, Baines M et al (2001) Clinical practice recommendations for the management of bowel obstruction in patients with end-stage cancer. Support Care Cancer 9:223–233CrossRefPubMed
12.
Zurück zum Zitat Santamaria LB, Fodale V, Mandolfino T et al (1991) Transdermal scopolamine reduces nausea, vomiting and sialorrhea in the postoperative period in teeth and mouth surgery. Minerva Anestesiol 57(9):686–687PubMed Santamaria LB, Fodale V, Mandolfino T et al (1991) Transdermal scopolamine reduces nausea, vomiting and sialorrhea in the postoperative period in teeth and mouth surgery. Minerva Anestesiol 57(9):686–687PubMed
13.
Zurück zum Zitat Savarese R, Diamond M, Elovic E, Millis SR (2004) Intraparotid injection of botulinum toxin A as a treatment to control sialorrhea in children with cerebral palsy. Am J Phys Med Rehabil 83(4):304–311PubMed Savarese R, Diamond M, Elovic E, Millis SR (2004) Intraparotid injection of botulinum toxin A as a treatment to control sialorrhea in children with cerebral palsy. Am J Phys Med Rehabil 83(4):304–311PubMed
14.
Zurück zum Zitat Serrano-Duenas M (2003) Sialorrhea in patients with Parkinson. A six year prospective study. Rev Neurol 37(7):623–626PubMed Serrano-Duenas M (2003) Sialorrhea in patients with Parkinson. A six year prospective study. Rev Neurol 37(7):623–626PubMed
15.
Zurück zum Zitat Shorthose K, Andrew ND (2003) Symptom prevalence in palliative care. Palliat Med 17(8):723–724PubMed Shorthose K, Andrew ND (2003) Symptom prevalence in palliative care. Palliat Med 17(8):723–724PubMed
16.
Zurück zum Zitat Stern Y, Feinmesser R, Collins M, Shott SR, Cotton RT (2002) Bilateral submandibular gland excision with parotid duct ligation for treatment of sialorrhea in children: long-term results. Arch Otolaryngol Head Neck Surg 128(7):801–803PubMed Stern Y, Feinmesser R, Collins M, Shott SR, Cotton RT (2002) Bilateral submandibular gland excision with parotid duct ligation for treatment of sialorrhea in children: long-term results. Arch Otolaryngol Head Neck Surg 128(7):801–803PubMed
17.
Zurück zum Zitat Suskind DL, Tilton A (2002) Clinical study of botulinum—a toxin in the treatment of sialorrhea in children with cerebral palsy. Laryngoscope 112(1):73–81CrossRefPubMed Suskind DL, Tilton A (2002) Clinical study of botulinum—a toxin in the treatment of sialorrhea in children with cerebral palsy. Laryngoscope 112(1):73–81CrossRefPubMed
18.
Zurück zum Zitat Tranmer JE, Heyland D, Dudgeon D, Groll D, Squires-Graham M et al (2003) Measuring the symptom experience of seriously ill cancer and non cancer hospitalized patients near the end of life with memorial symptom assessment scale. J Pain Symptom Manage 25:420–429CrossRefPubMed Tranmer JE, Heyland D, Dudgeon D, Groll D, Squires-Graham M et al (2003) Measuring the symptom experience of seriously ill cancer and non cancer hospitalized patients near the end of life with memorial symptom assessment scale. J Pain Symptom Manage 25:420–429CrossRefPubMed
19.
Zurück zum Zitat Tscheng DZ (2003) Sialorrhea-therapeutic drug options. Ann Pharmacother 36(11):1785–1790CrossRef Tscheng DZ (2003) Sialorrhea-therapeutic drug options. Ann Pharmacother 36(11):1785–1790CrossRef
Metadaten
Titel
Treating sialorrhea with transdermal scopolamine. Exploiting a side effect to treat an uncommon symptom in cancer patients
verfasst von
Davide Tassinari
Barbara Poggi
Manuela Fantini
Emiliano Tamburini
Sergio Sartori
Publikationsdatum
01.07.2005
Erschienen in
Supportive Care in Cancer / Ausgabe 7/2005
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-005-0826-3

Weitere Artikel der Ausgabe 7/2005

Supportive Care in Cancer 7/2005 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.